Business Context and Reporting Period
This Form 8-K Current Report from Harvard Bioscience, Inc. covers events occurring on May 30, 2025, and June 2, 2025. The filing details the resignation of a director, the appointment of new board members, and the results of the 2025 Annual Meeting of Stockholders.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial-related metric disclosed is the increase in authorized shares for the company's incentive plan.
- Incentive Plan Shares: As of December 31, 2024, 2,356,173 shares were available. Following stockholder approval on June 2, 2025, the reserve increased by 3,923,000 shares.
Material Changes
The filing reports significant changes to the Board of Directors and corporate governance:
- Director Resignation: Thomas Loewald resigned from the Board effective May 30, 2025. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- New Director Appointment: John D. Duke was appointed to the Board on June 2, 2025, as a Class II director (term expires at the 2026 annual meeting). He was also appointed to the Audit Committee and the Nominating and Governance Committee.
- Lead Independent Director: Katherine Eade was appointed as the Lead Independent Director on June 2, 2025.
- Compensation Plan Amendment: Stockholders approved the Amended and Restated 2021 Incentive Plan, increasing the number of shares available for issuance.
Guidance, Outlook, and Voting Results
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard disclosures. It reports the following voting results from the June 2, 2025, Annual Meeting:
- Proposal 1 (Election of Director James Green): Approved (23,563,965 votes for; 3,188,231 withheld).
- Proposal 2 (Ratification of Auditor Grant Thornton LLP): Approved (31,536,184 votes for; 116,407 against).
- Proposal 3 (Executive Compensation Advisory Vote): Approved (23,840,892 votes for; 2,542,426 against).
- Proposal 4 (Amended 2021 Incentive Plan): Approved (25,144,481 votes for; 1,370,420 against).
Compensation terms for the newly appointed director, John D. Duke, are expected to be determined later and disclosed in an amendment to this report.
Investor Verification Checklist
- Verify the specific compensation terms for new director John D. Duke in the upcoming amendment to this 8-K.
- Review the full text of the Amended and Restated 2021 Incentive Plan (Exhibit 10.1) to understand the mechanics of the 3,923,000 share increase.
- Confirm the impact of the board composition changes on committee quorums and future governance decisions.
- Check for any subsequent filings regarding the resignation of Thomas Loewald to ensure no undisclosed disagreements arose post-filing.